Source:http://linkedlifedata.com/resource/pubmed/id/10335936
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
3
|
pubmed:dateCreated |
1999-6-24
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
May
|
pubmed:issn |
0941-4355
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
7
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
160
|
pubmed:dateRevised |
2004-11-17
|
pubmed:meshHeading |
pubmed-meshheading:10335936-Antibiotics, Antitubercular,
pubmed-meshheading:10335936-Cholestasis,
pubmed-meshheading:10335936-Drug Resistance, Microbial,
pubmed-meshheading:10335936-Humans,
pubmed-meshheading:10335936-Immunocompromised Host,
pubmed-meshheading:10335936-Neoplasms,
pubmed-meshheading:10335936-Pruritus,
pubmed-meshheading:10335936-Rifampin
|
pubmed:year |
1999
|
pubmed:articleTitle |
Rifampicin as treatment for pruritus in malignant cholestasis: an example of an improper indication for anti-infective drugs.
|
pubmed:publicationType |
Letter
|